Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health Canada to launch the Phase 2a INFLAM MOTION “Proof-of-Concept” study for 4P004 in patients with knee osteoarthritis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326675460/en/
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis
The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Canada. It will enroll 129 patients to evaluate, for the first time, the efficacy of 4P004 in individuals with knee osteoarthritis.
4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti-catabolic, and anabolic benefits of GLP-1. Preclinical studies suggest that 4P004 may slow disease progression and improve joint function by modulating the biological pathways throughout all joint tissues. This positions 4P004 as a potential disease-modifying treatment with the potential to significantly improve patient outcomes.
Luc Boblet, CEO of 4MB, declared:“This authorization from Health Canada is a major milestone in the 4MB value creation path. Advancing the INFLAM MOTION study is an exciting step towards demonstrating the potential of 4P004 as the first disease-modifying osteoarthritis drug (DMOAD).”
The study’s primary objective is to assess the efficacy of a single intra-articular injection of 4P004 in reducing knee pain by week 4 and up to week 12. In addition, the study aims to assess knee structure evaluation by contrast-enhancement MRI and investigate new surrogate biomarkers for disease progression and delay to total knee replacement.
Francis Berenbaum, Chief Medical Officer of 4MB, added: “Following a strong demonstration of the safety and tolerability profile of 4P004 in the LASARE Phase 1 clinical trial, we aim to establish therapeutic potential and redefine treatment standards for knee osteoarthritis with the INFLAM MOTION Phase 2a study. The Health Canada authorization granted is an important milestone that allows us to move forward with confidence and continue to develop this innovative treatment option for patients.”
4MB will proceed with the study initiation in Canada, including the first patient enrolment, which is expected in the second quarter of 2025.
About 4Moving Biotech
Incorporated in mid-2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical-stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326675460/en/
Contacts
Press:
Emmanuel Dadje
Communication Manager - emmanuel.dadje@4P-Pharma.com
+33 6 30 06 12 13
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoquip Marine Secures €100million Bond to Accelerate Fleet Enhancements and Strategic Growth4.4.2025 09:00:00 CEST | Press Release
Geoquip Marine (Geoquip), a global leader in offshore geotechnical solutions and a Njord Partners portfolio company, is pleased to announce today it has successfully closed a €100million bond offering. This bond issuance significantly improves the Company’s cash balance, supports its continued growth, and is seen as a significant step in the Company’s ongoing maturation and development. The bond was placed after a successful roadshow with investors and will be used to advance key strategic initiatives. The immediate use of proceeds will be allocated between the repayment of existing debt and funding for two transformational projects: The Geoquip Silvretta: As announced in December, Geoquip Silvretta is currently in a shipyard in Norway undergoing work to create a state-of-the-art geotechnical services platform for the offshore energy sector. The vessel is on track to start operations in the first half of 2025. The Geoquip Elena: The Company is preparing to install a rig on Geoquip Elen
SES Announces Annual General Meeting Voting Results4.4.2025 08:50:00 CEST | Press Release
SES S.A. (“SES” or the “Company”) held the Company’s Annual General Meeting (“AGM”) at its headquarters in Betzdorf, Luxembourg, yesterday. The shareholders have voted all resolutions in accordance with the recommendations made by SES’s Board of Directors, notably the company’s 2024 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total amount includes the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) already paid to shareholders on 17 October 2024. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on 17 April 2025. Also as recommended by the Board of Directors, the shareholders approved the appointments of Mrs Ellen Lord and Mr John Shaw to the Board of Directors and the non-binding agenda item received from Atlas Infrastructure Partners regarding capital returns. “The outcome of the AGM is the result of SES’s ongoing commitment to productive shareholder engagement, ensur
ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy4.4.2025 08:00:00 CEST | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#
Western Union Offers Zero-Fee International Money Transfers to Myanmar4.4.2025 03:00:00 CEST | Press Release
In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the country. Effective immediately until midnight, 00:00 Myanmar Standard Time on 10 April 2025, individuals can send funds to Myanmar via WesternUnion.com or the Western Union mobile app, ensuring families can provide crucial support to their loved ones during this time of urgent need. Western Union remains committed to providing support during times of crisis, offering zero-fee transfers whenever possible to help communities in need. Money transfers sent to Myanmar will be: Available for payout into bank accounts. Available for payout into select mobile wallets Available for payouts incash at Agent locations2 “Our thoughts are with the people of Myanmar during this incredibly difficult time,” said Atish Shrestha, Western Union’s Regional Director for Indochina, South Korea and Taiwan, Western Un
Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal4.4.2025 00:07:00 CEST | Press Release
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for renewable battery applications. In its written opinion, the Boards of Appeal of the European Patent Office found Stora Enso's arguments brought before the board “not convincing” and agreed that a clarifying amendment to the claims did not extend the scope of protection of the patent. The ruling further affirms Aymium's position as the global leader in biocarbon materials for battery applications. Beyond the present ruling, Aymium owns a portfolio of more than 600 patents relating to biocarbon materials, compositions and manufacturing methods, including many specifically relevant to battery materials, and is the dominant global innovator regarding biocarbon materials. The ruling, combined with Aymium's massive patent portfolio, calls into question the ability of Stora Enso to produce bio-based ba
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom